본문 바로가기
KERD
논문KCI 등재후보

The role of glucagon-like peptide-1 receptor agonists (GLP1-RAs) in the management of the hypertensive patient with metabolic syndrome: a position paper from the Korean society of hypertension

고승현|유승기|Park Sungjoon|Kim Hyeon Chang|Cho In-Jeong|Ihm Sang Hyun|Lee Hae-Young|Kim Kyuho|Kim Song-Yi|Cho Eun Joo|Park Jae-Hyeong|Moon Min Kyong
대한고혈압학회 (The Korean Society of Hypertension)|2024.01|Clinical Hypertension|제30권 |pp. 24-24|DOI 10.1186/s40885-024-00279-4

0

조회

0

다운로드

0

인용

0

참고문헌

키워드

obesityMetabolic syndromehypertension1glucagonLike peptide1 receptor agonist

초록

Obesity is the one of the most important components of metabolic syndrome. Because obesity related hypertension accounts for two thirds of essential hypertension, managing obesity and metabolic syndrome is a crucial task in the management of hypertension. However, the current non-pharmacological therapies have limitations for achieving or maintaining ideal body weight. Recently, glucagon-like peptide-1 receptor agonists (GLP1-RAs) have demonstrated excellent weight control effects, accompanied by corresponding reductions in blood pressure. GLP1-RAs have shown cardiovascular and renal protective effects in cardiovascular outcome trials both in primary and secondary prevention. In this document, the Korean Society of Hypertension intends to remark the current clinical results of GLP1-RAs and recommend the government and health-policy makers to define obesity as a disease and to establish forward-looking policies for GLP1-RA treatment for obesity treatment, including active reimbursement policies.

Abstract

Obesity is the one of the most important components of metabolic syndrome. Because obesity related hypertension accounts for two thirds of essential hypertension, managing obesity and metabolic syndrome is a crucial task in the management of hypertension. However, the current non-pharmacological therapies have limitations for achieving or maintaining ideal body weight. Recently, glucagon-like peptide-1 receptor agonists (GLP1-RAs) have demonstrated excellent weight control effects, accompanied by corresponding reductions in blood pressure. GLP1-RAs have shown cardiovascular and renal protective effects in cardiovascular outcome trials both in primary and secondary prevention. In this document, the Korean Society of Hypertension intends to remark the current clinical results of GLP1-RAs and recommend the government and health-policy makers to define obesity as a disease and to establish forward-looking policies for GLP1-RA treatment for obesity treatment, including active reimbursement policies.

참고문헌 (133)

  1. Kahn R, "The metabolic syndrome : time for a critical appraisal : joint statement from the American Diabetes Association and the European Association for the Study of Diabetes", Diabetes Care, 28(9), pp.2289~2304 (2005)
  2. Wilson PWF, "Metabolic Syndrome as a Precursor of Cardiovascular Disease and Type 2 Diabetes Mellitus", Circulation, 112(20), pp.3066~3072 (2005)
  3. Kim HC, "Korea hypertension fact sheet 2022 : analysis of nationwide population-based data with a special focus on hypertension in the elderly", Clin Hypertens, 29(1), pp.22~ (2023)
  4. Jung MH, "Obesity-related hypertension and chronic kidney disease : from evaluation to management", Kidney research and clinical practice, 42(4), pp.431~444 (2023)
  5. Hall JE, "Obesity-induced hypertension : interaction of neurohumoral and renal mechanisms", Circulation Research, 116(6), pp.11991~11006 (2015)
  6. Park S, "Resistant hypertension : consensus document from the Korean society of hypertension", Clin Hypertens, 29(1), pp.30~ (2023)
  7. Lee SR, "Increased prevalence of metabolic syndrome among hypertensive population : ten years’trend of the Korean National Health and Nutrition Examination Survey", Int J Cardiol, 166(3), pp.633~639 (2013)
  8. Shin D, "Suboptimal control status of young hypertensive population", Clin Hypertens, 29(1), pp.13~ (2023)
  9. Kim HL, "The 2022 focused update of the 2018 Korean Hypertension Society Guidelines for the management of hypertension", Clin Hypertens, 29(1), pp.11~ (2023)
  10. Chowdhury MZI, "Hypertension prevalence and its trend in Bangladesh : evidence from a systematic review and meta-analysis", Clin Hypertens, 26, pp.10~ (2020)
  11. Khera A, "SELECTing Treatments for Cardiovascular Disease-Obesity in the Spotlight", N Engl J Med, 389(24), pp.2287~2288 (2023)
  12. Jensen MD, "2013 AHA", ACC, American Heart Association Task Force on Practice Guidelines and The Obesity Society, pp.Circulation, 2014[DOI]
  13. Shariq OA, "Obesity-related hypertension : a review of pathophysiology, management, and the role of metabolic surgery", Gland Surg, 9(1), pp.80~93 (2020)
  14. Ussher JR, "Glucagon-like peptide 1 receptor agonists : cardiovascular benefits and mechanisms of action", Nat Rev Cardiol, 20(7), pp.463~474 (2023)
  15. NCD Risk Factor Collaboration(NCD-RisC), "Heterogeneous contributions of change in population distribution of body mass index to change in obesity and underweight", Elife, 10, pp.e60060~ (2021)
  16. Landsberg L, "Obesity-related hypertension : pathogenesis, cardiovascular risk, and treatment : a position paper of The Obesity Society and the American Society of Hypertension", J Clin Hypertens(Greenwich), 15(1), pp.14~33 (2013)
  17. Bluher M, "Obesity : global epidemiology and pathogenesis", Nat Rev Endocrinol, 15(5), pp.288~298 (2019)
  18. Collaboration NCDRF, "Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128.9 million children, adolescents, and adults", Lancet, 390(10113), pp.2627~2642 (2017)
  19. Collaboration NCDRF, "Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019 : a pooled analysis of 1201 population-representative studies with 104 million participants", Lancet, 398(10304), pp.957~980 (2021)
  20. Schutte AE, "Addressing global disparities in blood pressure control : perspectives of the International Society of Hypertension", Cardiovasc Res, 119(2), pp.381~409 (2023)
  21. Park D, "20-Year Trends in Metabolic Syndrome Among Korean Adults From 2001 to 2020", JACC : Asia, 3(3_Part_2), pp.491~502 (2023)
  22. Kim Y, "Trends in the prevalence and management of major metabolic risk factors for chronic disease over 20 years : findings from the 1998–2018 Korea National Health and Nutrition Examination Survey", Epidemiol Health, 43, pp.e2021028~ (2021)
  23. Lee GB, "Obesity, hypertension, diabetes mellitus, and hypercholesterolemia in Korean adults before and during the COVID-19 pandemic : a special report of the 2020 Korea National Health and Nutrition Examination Survey", Epidemiol Health, 44, pp.e2022041~ (2022)
  24. Onuh JO, "Metabolomics profiling in hypertension and blood pressure regulation : a review", Clin Hypertens, 26(1), pp.23~ (2020)
  25. American College of Cardiology, "Expert Panel Report: Guidelines (2013) for the management of overweight and obesity in adults", Obesity, 22(Suppl 2), pp.S41~S410 (2014)
  26. Foster GD, "A randomized trial of a low-carbohydrate diet for obesity", N Engl J Med, 348(21), pp.2082~2090 (2003)
  27. Choi JH, "Effect of carbohydrate-restricted diets and intermittent fasting on obesity, type 2 diabetes mellitus, and hypertension management : consensus statement of the Korean Society for the Study of obesity, Korean Diabetes Association, and Korean Society of Hypertension", Clin Hypertens, 28(1), pp.26~ (2022)
  28. Ge L, "Comparison of dietary macronutrient patterns of 14 popular named dietary programmes for weight and cardiovascular risk factor reduction in adults : systematic review and network meta-analysis of randomised trials", BMJ, 369, pp.m696~ (2020)
  29. Rondanelli M, "Current opinion on dietary advice in order to preserve fat-free mass during a low-calorie diet", Nutrition, 72, pp.110667~ (2020)
  30. Bellicha A, "Effect of exercise training on weight loss, body composition changes, and weight maintenance in adults with overweight or obesity : An overview of 12 systematic reviews and 149 studies", Obes Rev, 4(Suppl 4), pp.e13256~ (2021)
  31. Kim KK, "Evaluation and Treatment of Obesity and Its Comorbidities : 2022 Update of Clinical Practice Guidelines for Obesity by the Korean Society for the Study of Obesity", J Obes Metab Syndr, 32(1), pp.1~24 (2023)
  32. Kim BY, "2020 Korean Society for the Study of Obesity Guidelines for the Management of Obesity in Korea", J Obes Metab Syndr, 30(2), pp.81~92 (2021)
  33. Kim BY, "Current Long-Term Pharmacotherapies for the Management of Obesity", J Obes Metab Syndr, 29(2), pp.99~109 (2020)
  34. Garvey WT, "American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity", Endocr Pract, 22(Suppl 3), pp.1~203 (2016)
  35. Bayliss WM, "The mechanism of pancreatic secretion", J Physiol, 28(5), pp.325~353 (1902)
  36. Brown JC, "Further purification of a polypeptide demonstrating enterogastrone activity", J Physiol, 209(1), pp.57~64 (1970)
  37. Bell GI, "Exon duplication and divergence in the human preproglucagon gene", Nature, 304(5924), pp.368~371 (1983)
  38. but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus, "J Clin Invest", 1993, 301~307
  39. Deacon CF, "Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects", Diabetes, 44(9), pp.1126~1131 (1995)
  40. Sharma D, "Recent updates on GLP-1agonists : Current advancements & challenges", Biomed Pharmacother, 108, pp.952~962 (2018)
  41. Meier JJ, "GLP-1 receptor agonists for individualized treatment of type 2diabetes mellitus", Nat Rev Endocrinol, 8(12), pp.728~742 (2012)
  42. Buckley ST, "Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist", Sci Transl Med, 10(467) (2018)
  43. Merchenthaler I, "Distribution of pre-pro-glucagon and glucagon-like peptide-1 receptor messenger RNAs in the rat central nervous system", J Comp Neurol, 403(2), pp.261~280 (1999)
  44. Ban K, "Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and-independent pathways", Circulation, 117(18), pp.2340~2350 (2008)
  45. Nauck MA, "GLP-1 receptor agonists in the treatment of type 2 diabetes-state-of-the-art", Mol Metab, 46, pp.101102~ (2021)
  46. Carabotti M, "The gut-brain axis : interactions between enteric microbiota, central and enteric nervous systems", Ann Gastroenterol, 28(2), pp.203~209 (2015)
  47. Salehi M, "The Role of Glucagon-Like Peptide-1 in Energy Homeostasis", Metab Syndr Relat Disord, 17(4), pp.183~191 (2019)
  48. Drucker DJ, "The incretin system : glucagon-like peptide-1receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes", Lancet, 368(9548), pp.1696~1705 (2006)
  49. Nauck M, "Adding liraglutide to oral antidiabetic drug monotherapy : efficacy and weight benefits", Postgrad Med, 121(3), pp.5~15 (2009)
  50. Davies MJ, "Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes : The SCALE Diabetes Randomized Clinical Trial", JAMA, 314(7), pp.687~699 (2015)
  51. Secher A, "The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss", J Clin Invest, 124(10), pp.4473~4488 (2014)
  52. Gabery S, "Semaglutide lowers body weight in rodents via distributed neural pathways", JCI Insight, 5(6), pp.e133429~ (2020)
  53. Blundell J, "Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity", Diabetes Obes Metab, 19(9), pp.1242~1251 (2017)
  54. Kadouh H, "GLP-1 Analog Modulates Appetite, Taste Preference, Gut Hormones, and Regional Body Fat Stores in Adults with Obesity", J Clin Endocrinol Metab, 105(5), pp.1552~1563 (2020)
  55. ElSayed NA, "3. Prevention or Delay of Type 2 Diabetes and Associated Comorbidities: Standards of Care in Diabetes-2023", Diabetes Care, 46(Suppl 1), pp.S41~S48 (2023)
  56. Hamman RF, "Effect of weight loss with lifestyle intervention on risk of diabetes", Diabetes Care, 29(9), pp.2102~2107 (2006)
  57. Lean ME, "Primary care-led weight management for remission of type 2diabetes(DiRECT) : an open-label, cluster-randomised trial", Lancet, 391(10120), pp.541~551 (2018)
  58. Christensen P, "Men and women respond differently to rapid weight loss : Metabolic outcomes of a multi-centre intervention study after a low-energy diet in 2500 overweight, individuals with prediabetes(PREVIEW)", Diabetes Obes Metab, 20(12), pp.2840~2851 (2018)
  59. Taha MB, "Glucagon-Like Peptide 1 Receptor Agonists : A Medication for Obesity Management", Curr Atheroscler Rep, 24(8), pp.643~654 (2022)
  60. Pi-Sunyer X, "A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management", N Engl J Med, 373(1), pp.11~22 (2015)
  61. le Roux CW, "3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes : a randomised, double-blind trial", Lancet, 389(10077), pp.1399~1409 (2017)
  62. Wilding JPH, "Once-Weekly Semaglutide in Adults with Overweight or Obesity", N Engl J Med, 384(11), pp.989~1002 (2021)
  63. Wang W, "Effects of treatment with Glucagon-like peptide-1 receptor agonist on prediabetes with overweight", obesity : A systematic review and meta-analysis, 2023, pp.39(7), e3680~
  64. Yeh TL, "Effect of glucagon-like peptide-1 receptor agonists on glycemic control, and weight reduction in adults : A multivariate meta-analysis", PLoS ONE, 18(1), pp.e0278685~ (2023)
  65. Bae JH, "Diabetes Fact Sheet in Korea 2021", Diabetes Metab J, 46(3), pp.417~426 (2022)
  66. Asmar A, "Renal extraction and acute effects of glucagon-like peptide-1 on central and renal hemodynamics in healthy men", American Journal of Physiology-Endocrinology and Metabolism, 308(8), pp.E641~E649 (2015)
  67. Pfeffer MA, "Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome", N Engl J Med, 373(23), pp.2247~2257 (2015)
  68. Marso SP, "Semaglutide and Cardiovascular Outcomes in Patients with Type 2Diabetes", N Engl J Med, 375(19), pp.1834~1844 (2016)
  69. Marso SP, "Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes", N Engl J Med, 375(4), pp.311~322 (2016)
  70. Holman RR, "Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes", N Engl J Med, 377(13), pp.1228~1239 (2017)
  71. Hernandez AF, "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease(Harmony Outcomes) : a double-blind, randomised placebo-controlled trial", Lancet, 392(10157), pp.1519~1529 (2018)
  72. Gerstein HC, "Dulaglutide and cardiovascular outcomes in type 2 diabetes(REWIND) : a double-blind, randomised placebo-controlled trial", Lancet, 394(10193), pp.121~130 (2019)
  73. Husain M, "Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes", N Engl J Med, 381(9), pp.841~851 (2019)
  74. Kosiborod MN, "Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity", N Engl J Med, 389(12), pp.1069~1084 (2023)
  75. Lincoff AM, "Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes", N Engl J Med, 389(24), pp.2221~2232 (2023)
  76. Sun F, "Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes : a systematic review and network metaanalysis", Diabetes Res Clin Pract, 110(1), pp.26~37 (2015)
  77. Goud A, "GLP-1 agonists and blood pressure : a review of the evidence", Curr Hypertens Rep, 18, pp.1~11 (2016)
  78. Ribeiro-Silva JC, "The blood pressure lowering effects of glucagon-like peptide-1 receptor agonists : A mini-review of the potential mechanisms", Curr Opin Pharmacol, 69, pp.102355~ (2023)
  79. Hu M, "Effect of hemoglobin A1c reduction or weight reduction on blood pressure in glucagon-like peptide-1 receptor agonist and sodium-glucose cotransporter-2 inhibitor treatment in type 2 diabetes mellitus : a meta-analysis", J Am Heart Assoc, 9(7), pp.e015323~ (2020)
  80. Ferdinand KC, "Effects of the once-weekly glucagon-like peptide-1 receptor agonist dulaglutide on ambulatory blood pressure and heart rate in patients with type 2 diabetes mellitus", Hypertension, 64(4), pp.731~737 (2014)
  81. Fonseca VA, "Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes : insights from a patient-level pooled analysis of six randomized clinical trials", J Diabetes Complications, 28(3), pp.399~405 (2014)
  82. Gaspari T, "A GLP-1 receptor agonist liraglutide inhibits endothelial cell dysfunction and vascular adhesion molecule expression in an ApoE-", -mouse model, 2011, pp.8(2), 117~124
  83. Nyström T, "Glucagon-like peptide-1relaxes rat conduit arteries via an endothelium-independent mechanism", Regul Pept, 125(1–3), pp.173~177 (2005)
  84. Fan S-H, "Glucagon-like peptide 1 treatment reverses vascular remodelling by downregulating matrix metalloproteinase 1 expression through inhibition of the ERK1", 2, Mol Cell Endocrinol, pp.2020, 518[DOI]
  85. Kim M, "GLP-1receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure", Nat Med, 19(5), pp.567~575 (2013)
  86. Moreno C, "Renal effects of glucagon-like peptide in rats", Eur J Pharmacol, 434(3), pp.163~167 (2002)
  87. Gutzwiller J-P, "Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men", J Clin Endocrinol Metab, 89(6), pp.3055~3061 (2004)
  88. Katsurada K, "Central glucagon-like peptide-1 receptor signaling via brainstem catecholamine neurons counteracts hypertension in spontaneously hypertensive rats", Sci Rep, 9(1), pp.12986~ (2019)
  89. Pauza AG, "GLP1R attenuates sympathetic response to high glucose via carotid body inhibition", Circ Res, 130(5), pp.694~707 (2022)
  90. Hattori Y, "A glucagon-like peptide-1(GLP-1)analogue, liraglutide, upregulates nitric oxide production and exerts anti-inflammatory action in endothelial cells", Diabetologia, 53(10), pp.2256~2263 (2010)
  91. Ishibashi Y, "Glucagon-like peptide-1(GLP-1)inhibits advanced glycation end product(AGE)-induced upregulation of VCAM-1 mRNA levels in endothelial cells by suppressing AGE receptor(RAGE)expression", Biochem Biophys Res Commun, 391(3), pp.1405~1408 (2010)
  92. Luna-Marco C, "Effects of GLP-1receptor agonists on mitochondrial function, inflammatory markers and leukocyte-endothelium interactions in type 2 diabetes", Redox Biol, 66, pp.102849~ (2023)
  93. Rakipovski G, "The GLP-1 Analogs Liraglutide and Semaglutide Reduce Atherosclerosis in ApoE-", -and LDLr-, JACC : Basic to Translational Science, pp.2018, 3(6)[DOI]
  94. Anholm C, "Liraglutide in combination with metformin may improve the atherogenic lipid profile and decrease C-reactive protein level in statin treated obese patients with coronary artery disease and newly diagnosed type 2 diabetes : A randomized trial", Atherosclerosis, 288, pp.60~66 (2019)
  95. Roessler J, "Modulatory role of gut microbiota in cholesterol and glucose metabolism : Potential implications for atherosclerotic cardiovascular disease", Atherosclerosis, 359, pp.1~12 (2022)
  96. Holst JJ, "Glucagon-like peptide-1, glucose homeostasis and diabetes", Trends Mol Med, 14(4), pp.161~168 (2008)
  97. Jojima T, "Liraglutide, a GLP-1 receptor agonist, inhibits vascular smooth muscle cell proliferation by enhancing AMP-activated protein kinase and cell cycle regulation, and delays atherosclerosis in ApoE deficient mice", Atherosclerosis, 261, pp.44~51 (2017)
  98. Scalzo RL, "Sitagliptin improves diastolic cardiac function but not cardiorespiratory fitness in adults with type 2 diabetes", J Diabetes Complications, 33(8), pp.561~566 (2019)
  99. Nomoto H, "A Comparison of the Effects of the GLP-1 Analogue Liraglutide and Insulin Glargine on Endothelial Function and Metabolic Parameters : A Randomized, Controlled Trial Sapporo Athero-Incretin Study 2(SAIS2)", PLoS ONE, 10(8), pp.e0135854~ (2015)
  100. Li Q, "GLP-1 Inhibits High-Glucose-Induced Oxidative Injury of Vascular Endothelial Cells", Sci Rep, 7(1), pp.8008~ (2017)
  101. Cameron-Vendrig A, "Glucagon-Like Peptide 1 Receptor Activation Attenuates Platelet Aggregation and Thrombosis", Diabetes, 65(6), pp.1714~1723 (2016)
  102. Kristensen SL, "Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes : a systematic review and meta-analysis of cardiovascular outcome trials", Lancet Diabetes Endocrinol, 7(10), pp.776~785 (2019)
  103. Sattar N, "Cardiovascular, mortality, and kidney outcomes with GLP-1receptor agonists in patients with type 2 diabetes : a systematic review and meta-analysis of randomised trials", Lancet Diabetes Endocrinol, 9(10), pp.653~662 (2021)
  104. Banerjee M, "GLP-1 Receptor Agonists and Risk of Adverse Cerebrovascular Outcomes in Type 2 Diabetes : A Systematic Review and Meta-Analysis of Randomized Controlled Trials", J Clin Endocrinol Metab, 108(7), pp.1806~1812 (2023)
  105. Gerstein HC, "The effect of dulaglutide on stroke : an exploratory analysis of the REWIND trial", Lancet Diabetes Endocrinol, 8(2), pp.106~114 (2020)
  106. Strain WD, "Effects of Semaglutide on Stroke Subtypes in Type 2 Diabetes : Post Hoc Analysis of the Randomized SUSTAIN 6 and PIONEER 6", Stroke, 53(9), pp.2749~2757 (2022)
  107. Caruso I, "Cardiovascular and Renal Effectiveness of GLP-1 Receptor Agonists vs. Other Glucose-Lowering Drugs in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Real-World Studies", Metabolites, 12(2), pp.183~ (2022)
  108. Muskiet MHA, "GLP-1 and the kidney : from physiology to pharmacology and outcomes in diabetes", Nat Rev Nephrol, 13(10), pp.605~628 (2017)
  109. Shim SY, "Ideal cardiovascular health metrics and the risk of nonalcoholic fatty liver disease in Korean adults", Clin Hypertens, 29(1), pp.3~ (2023)
  110. Eguchi Y, "Pilot study of liraglutide effects in non-alcoholic steatohepatitis and non-alcoholic fatty liver disease with glucose intolerance in Japanese patients(LEAN-J)", Hepatol Res, 45(3), pp.269~278 (2015)
  111. Trujillo J, "Safety and tolerability of once-weekly GLP-1 receptor agonists in type 2 diabetes", J Clin Pharm Ther, 45(Suppl 1), pp.43~60 (2020)
  112. Bettge K, "Occurrence of nausea vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists : A systematic analysis of published clinical trials", Diabetes Obes Metab, 19(3), pp.336~347 (2017)
  113. He L, "Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases : A Systematic Review and Meta-analysis of Randomized Clinical Trials", JAMA Intern Med, 182(5), pp.513~519 (2022)
  114. Woronow D, "Acute Cholecystitis Associated With the Use of Glucagon-Like Peptide-1 Receptor Agonists Reported to the US Food and Drug Administration", JAMA Intern Med, 182(10), pp.1104~1106 (2022)
  115. Gier B, "Chronic GLP-1 receptor activation by exendin-4 induces expansion of pancreatic duct glands in rats and accelerates formation of dysplastic lesions and chronic pancreatitis in the Kras(G12D)mouse model", Diabetes, 61(5), pp.1250~1262 (2012)
  116. Egan AG, "Pancreatic safety of incretin-based drugs–FDA and EMA assessment", N Engl J Med, 370(9), pp.794~797 (2014)
  117. Filippatos TD, "Adverse Effects of GLP-1Receptor Agonists", Rev Diabet Stud, 11(3–4), pp.202~230 (2014)
  118. Bjerre Knudsen L, "Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation", Endocrinology, 151(4), pp.1473~1486 (2010)
  119. Vangoitsenhoven R, "GLP1 and cancer:friend or foe?", Endocr Relat Cancer, 19(5), pp.F77~F88 (2012)
  120. Pradhan R, "Glucagon-Like Peptide 1 Receptor Agonists and Risk of Anaphylactic Reaction Among Patients With Type 2 Diabetes : A Multisite Population-Based Cohort Study", Am J Epidemiol, 191(8), pp.1352~1367 (2022)
  121. Davies MJ, "Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)", Diabetologia, 65(12), pp.1925~1966 (2022)
  122. Cosentino F, "2019ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD", Eur Heart J, 41(2), pp.255~323 (2020)
  123. Cawley J, "Direct medical costs of obesity in the United States and the most populous states", J Manag Care Spec Pharm, 27(3), pp.354~366 (2021)
  124. Visscher TL, "The public health impact of obesity", Annu Rev Public Health, 22, pp.355~375 (2001)
  125. Gomez Lumbreras A, "Cost-effectiveness analysis of five anti-obesity medications from a US payer’s perspective", Nutr Metab Cardiovasc Dis, 33(6), pp.1268~1276 (2023)
  126. Hu Y, "Cost-effectiveness analysis of 4 GLP-1RAs in the treatment of obesity in a US setting", Ann Transl Med, 10(3), pp.152~ (2022)
  127. Kim N, "Costeffectiveness analysis of semaglutide 2.4 mg for the treatment of adult patients with overweight and obesity in the United States", J Manag Care Spec Pharm, 28(7), pp.740~752 (2022)
  128. Lim F, "Cost-Effectiveness of Pharmacotherapy for the Treatment of Obesity in Adolescents", JAMA Netw Open, 6(8), pp.e2329178~ (2023)
  129. Saumoy M, "Cost-effectiveness of endoscopic, surgical and pharmacological obesity therapies : a microsimulation and threshold analyses", Gut, 72(12), pp.2250~2259 (2023)
  130. Jannah N, "Coverage for Obesity Prevention and Treatment Services : Analysis of Medicaid and State Employee Health Insurance Programs", Obesity(Silver Spring), 26(12), pp.1834~1840 (2018)
  131. Eberly LA, "Racial, Ethnic, and Socioeconomic Inequities in Glucagon-Like Peptide-1Receptor Agonist Use Among Patients With Diabetes in the US", JAMA Health Forum, 2(12), pp.e214182~ (2021)
  132. Global H, "Expanding access to newer medicines for people with type 2 diabetes in low-income and middle-income countries : a cost-effectiveness and price target analysis", Lancet Diabetes Endocrinol, 9(12), pp.825~836 (2021)
  133. Tokarek J, "Molecular Processes Involved in the Shared Pathways between Cardiovascular Diseases and Diabetes", Biomedicines, 11(10), pp.2611~ (2023)

관련 논문AI추천

GLP-1수용체작용제의 신장 보호 효과에 대한 최신 지견배은희, 최홍상대한내과학회 · 대한내과학회지2025 · 제100권 제2호인크레틴 기반 비만 치료제의 최근 발전 상황최덕현대한내과학회 · 대한내과학회지2024 · 제99권 제2호Antihyperglycemic agent therapy for adult patients with type 2 diabetes mellitus 2017: a position statement of the Korean Diabetes Association고승현, 김난희, 김진화, 김현진, 문민경, 박석오, 이병완, 이상열, 최경묵, 허규연, the Committee of Clinical Practice Guideline of KDA대한내과학회 · The Korean Journal of Internal Medicine2017 · 제32권 제6호비만 치료에서 semaglutide의 효능 및 안전성에 대한 고찰박태은, 한승훈한국임상약학회 · 한국임상약학회지2024 · 제34권 제1호Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes이동윤, 이승아대한소아내분비학회 · Annals of Pediatric Endocrinology & Metabolism2017 · 제22권 제1호고혈압 환자에서 대사증후군 평가의 유용성김대중, 김영권, 김철호, 박정배, 성기철, 이소령, 이인규, 이혜영, 조은주, 현민수대한고혈압학회 · Clinical Hypertension2011 · 제17권 제3호

이 간행물의 다른 논문 (35건)

Sex disparities in physical activity domains and hypertension prevalenceJung Yong Joon, 조민정, Jae Sae Young, Kim Hyun Jeong, Min Ho Jeong, Kunutsor Setor Kpp. 1-1Effect of low sodium and high potassium diet on lowering blood pressure and cardiovascular eventsYu Mi-yeon, Shin Jinho, 김병식pp. 2-2The association between body mass index and abdominal obesity with hypertension among South Asian population: findings from nationally representative surveysHaider Mohammad Rifat, Akonde Maxwell, Haider Shams Shabab, Pinky Susmita Dey, Pulock Orindom Shing, Kothadia Rohan Jay, Parray Ateeb Ahmad, Gupta Rajat Daspp. 3-3Elevated blood pressure among children born to women with obstructed labour in Eastern Uganda: a cohort studyWamulugwa Joan, Nahurira Doreck, Okello Dedan, Ssegawa Lawrence, Wandabwa Julius, Kiguli Sarah, Chebet Martin, Mukunya David, Musaba Milton W., Nambozo Brendah, Oguttu Faith, Makoko Brian Tonny, Napyo Agnes, Nantale Ritah, Wani Solomon, Tumuhamye Josephine, Auma Prossy, Atim Kettypp. 4-4The mediating effect of sleep disturbance on the association between hypertension and depression: a national data analysisLatief Kamaluddin, Sujarwadi Mokh, Hasan Faizul, Sithichoksakulchai Siriluk, Akyirem Samuel, Nurrika Dietapp. 5-5
원문 보기